Creative Planning acquired a new stake in shares of T2 Biosystems Inc (NASDAQ:TTOO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,000 shares of the medical equipment provider’s stock, valued at approximately $43,000.
A number of other hedge funds also recently modified their holdings of TTOO. Private Advisor Group LLC purchased a new stake in T2 Biosystems during the second quarter valued at approximately $27,000. Macquarie Group Ltd. purchased a new stake in T2 Biosystems during the second quarter valued at approximately $27,000. Commonwealth Equity Services LLC purchased a new stake in T2 Biosystems during the third quarter valued at approximately $32,000. Tower Research Capital LLC TRC raised its position in T2 Biosystems by 1,217.6% during the second quarter. Tower Research Capital LLC TRC now owns 22,399 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 20,699 shares during the period. Finally, Wiley BROS. Aintree Capital LLC raised its position in T2 Biosystems by 150.0% during the second quarter. Wiley BROS. Aintree Capital LLC now owns 25,000 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 37.75% of the company’s stock.
Shares of NASDAQ TTOO opened at $1.75 on Tuesday. The business’s 50 day moving average price is $2.43 and its 200-day moving average price is $1.95. T2 Biosystems Inc has a fifty-two week low of $0.52 and a fifty-two week high of $5.38. The company has a market cap of $67.25 million, a price-to-earnings ratio of -1.39 and a beta of 1.23.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Featured Story: What is the outlook for the FAANG stocks?
Want to see what other hedge funds are holding TTOO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for T2 Biosystems Inc (NASDAQ:TTOO).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.